You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 17, 2025

CLINICAL TRIALS PROFILE FOR DOPAMINE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for Dopamine Hydrochloride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT00405912 ↗ St. John's Wort for Tobacco Cessation Completed National Cancer Institute (NCI) Phase 2 2005-09-01 After a steady decline for the last 50 years, the prevalence of tobacco use in the United States has reached a plateau of approximately 23%. Currently available treatments among adults are expensive and not efficacious for all tobacco users. New pharmacologic agents need to be developed and tested to achieve the Healthy People 2010 goal of less than a 12% adult tobacco use prevalence. Bupropion, an FDA approved agent for tobacco cessation, acts by inhibiting central synaptosomal reuptake of dopamine and norepinephrine. A widely used herbal antidepressant, St. John's Wort (SJW), shares a similar mechanism of action and is effective for treating mild to moderate depression. SJW is well tolerated, available over the counter, and is significantly less expensive than the established treatments for tobacco dependence. To date, no prospective clinical trial evaluating the efficacy of SJW for the treatment of tobacco use has been published. We propose to evaluate the efficacy of SJW for increasing tobacco abstinence and decreasing nicotine withdrawal symptoms in a randomized, double-blind, placebo-controlled, three-arm, parallel group, dose-ranging clinical trial. Participants (N=120) will be randomly assigned to one of the three groups and will receive a twelve-week course of SJW 900 mg per day, 1800 mg per day, or a matching placebo. This study is anticipated to provide the data needed to develop a larger randomized controlled clinical trial submitted through the R01 funding mechanism.
OTC NCT00405912 ↗ St. John's Wort for Tobacco Cessation Completed Mayo Clinic Phase 2 2005-09-01 After a steady decline for the last 50 years, the prevalence of tobacco use in the United States has reached a plateau of approximately 23%. Currently available treatments among adults are expensive and not efficacious for all tobacco users. New pharmacologic agents need to be developed and tested to achieve the Healthy People 2010 goal of less than a 12% adult tobacco use prevalence. Bupropion, an FDA approved agent for tobacco cessation, acts by inhibiting central synaptosomal reuptake of dopamine and norepinephrine. A widely used herbal antidepressant, St. John's Wort (SJW), shares a similar mechanism of action and is effective for treating mild to moderate depression. SJW is well tolerated, available over the counter, and is significantly less expensive than the established treatments for tobacco dependence. To date, no prospective clinical trial evaluating the efficacy of SJW for the treatment of tobacco use has been published. We propose to evaluate the efficacy of SJW for increasing tobacco abstinence and decreasing nicotine withdrawal symptoms in a randomized, double-blind, placebo-controlled, three-arm, parallel group, dose-ranging clinical trial. Participants (N=120) will be randomly assigned to one of the three groups and will receive a twelve-week course of SJW 900 mg per day, 1800 mg per day, or a matching placebo. This study is anticipated to provide the data needed to develop a larger randomized controlled clinical trial submitted through the R01 funding mechanism.
New Formulation NCT00640159 ↗ Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease Completed Baylor College of Medicine Phase 4 2007-01-01 Parkinson's disease (PD) is a progressive neurodegenerative disease. Symptomatic therapy is primarily aimed at restoring dopamine function in the brain. Oral selegiline in conjunction with L-dopa has been a mainstay of therapy for PD patients experiencing motor fluctuations for many years. The mechanisms accounting for selegiline's beneficial adjunctive action in the treatment of PD are not fully understood. Inhibition of monoamine oxidase (MAO) type B (MAO-B) activity is generally considered to be of primary importance. Oral selegiline has low bio-availability and is typically dosed BID, for a total of 5-10 mg daily. Recently, the FDA approved a new orally disintegration tablet (ODT) formulation of selegiline, called ZelaparTM. This new formulation utilizes Zydis technology to dissolve in the mouth, with absorption through the oral mucosa, thereby largely bypassing the gut and avoiding first pass hepatic metabolism. This allows more active drug to be delivered at a lower dose. Consequently, Zelapar is dosed once-daily, up to 2.5 mg per day. There are no empirical data indicating whether the use of the new approved formulation of selegiline ODT (Zelapar) is superior or preferred by patients compared to traditional oral selegiline. It is believed that clinical efficacy will be preserved or enhanced, by delivering more active drug, with improved patient preference for the ODT formulation due to the once-daily dosing . The effectiveness of orally disintegrating selegiline as an adjunct to carbidopa/levodopa in the treatment of PD was established in a multicenter randomized placebo-controlled trial (n=140; 94 received orally disintegrating selegiline, 46 received placebo) of three months' duration. Patients randomized to orally disintegrating selegiline received a daily dose of 1.25 mg for the first 6 weeks and a daily dose of 2.5 mg for the last 6 weeks. Patients were all treated with levodopa and could additionally have been on dopamine agonists, anticholinergics, amantadine, or any combination of these during the trial. At 12 weeks, orally disintegrating selegiline-treated patients had an average of 2.2 hours per day less "OFF" time compared to baseline. Placebo treated patients had 0.6 hours per day less "OFF" time compared to baseline. These differences were significant (p < 0.001). Adverse events were very similar between drug and placebo.
OTC NCT00722124 ↗ S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence Completed Pharmavite Phase 2/Phase 3 2008-09-01 Cigarette smoking is of great public health importance and is the single most important preventable cause of morbidity, mortality and excess health care costs in the United States. After a steady decline for the last 50 years, the prevalence of tobacco use in the United States has reached a plateau of approximately 21%. Currently available treatments among adults are not efficacious for all tobacco users. New pharmacologic agents thus need to be continually developed and tested. The release of dopamine in the nucleus accumbens is one of the key components of the pleasurable and rewarding effects of nicotine. Drugs that increase monoamine neurotransmitter availability (particularly dopamine and norepinephrine) are likely to increase the reward function and thus ameliorate withdrawal symptoms. S-Adenosyl-L-Methionine (SAMe), the primary methyl donor for the central nervous system (CNS), donates methyl groups towards presynaptic synthesis of CNS monoamine neurotransmitters. By facilitating the synthesis of dopamine and norepinephrine in the brain, SAMe is likely to ameliorate the symptoms of nicotine withdrawal, thus improving tobacco abstinence rates in smokers who are trying to stop smoking. SAMe is well tolerated and is available over-the-counter. To date, no prospective clinical trial evaluating the efficacy of SAMe for the treatment of tobacco dependence has been published. We propose to evaluate the efficacy of SAMe for increasing smoking abstinence and decreasing nicotine withdrawal symptoms in a randomized, blinded, placebo-controlled, three-arm, parallel-group, dose-ranging phase II clinical trial. Participants (N=120) will be randomly assigned to one of the three groups, and will receive an 8-week course of SAMe 800-mg per day, 1600-mg per day, or a matching placebo. This study is anticipated to provide the data needed to develop a larger randomized controlled clinical trial submitted through the R01 funding mechanism, if the results appear promising.
OTC NCT00722124 ↗ S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence Completed Pharmavite LLC Phase 2/Phase 3 2008-09-01 Cigarette smoking is of great public health importance and is the single most important preventable cause of morbidity, mortality and excess health care costs in the United States. After a steady decline for the last 50 years, the prevalence of tobacco use in the United States has reached a plateau of approximately 21%. Currently available treatments among adults are not efficacious for all tobacco users. New pharmacologic agents thus need to be continually developed and tested. The release of dopamine in the nucleus accumbens is one of the key components of the pleasurable and rewarding effects of nicotine. Drugs that increase monoamine neurotransmitter availability (particularly dopamine and norepinephrine) are likely to increase the reward function and thus ameliorate withdrawal symptoms. S-Adenosyl-L-Methionine (SAMe), the primary methyl donor for the central nervous system (CNS), donates methyl groups towards presynaptic synthesis of CNS monoamine neurotransmitters. By facilitating the synthesis of dopamine and norepinephrine in the brain, SAMe is likely to ameliorate the symptoms of nicotine withdrawal, thus improving tobacco abstinence rates in smokers who are trying to stop smoking. SAMe is well tolerated and is available over-the-counter. To date, no prospective clinical trial evaluating the efficacy of SAMe for the treatment of tobacco dependence has been published. We propose to evaluate the efficacy of SAMe for increasing smoking abstinence and decreasing nicotine withdrawal symptoms in a randomized, blinded, placebo-controlled, three-arm, parallel-group, dose-ranging phase II clinical trial. Participants (N=120) will be randomly assigned to one of the three groups, and will receive an 8-week course of SAMe 800-mg per day, 1600-mg per day, or a matching placebo. This study is anticipated to provide the data needed to develop a larger randomized controlled clinical trial submitted through the R01 funding mechanism, if the results appear promising.
OTC NCT00722124 ↗ S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence Completed Mayo Clinic Phase 2/Phase 3 2008-09-01 Cigarette smoking is of great public health importance and is the single most important preventable cause of morbidity, mortality and excess health care costs in the United States. After a steady decline for the last 50 years, the prevalence of tobacco use in the United States has reached a plateau of approximately 21%. Currently available treatments among adults are not efficacious for all tobacco users. New pharmacologic agents thus need to be continually developed and tested. The release of dopamine in the nucleus accumbens is one of the key components of the pleasurable and rewarding effects of nicotine. Drugs that increase monoamine neurotransmitter availability (particularly dopamine and norepinephrine) are likely to increase the reward function and thus ameliorate withdrawal symptoms. S-Adenosyl-L-Methionine (SAMe), the primary methyl donor for the central nervous system (CNS), donates methyl groups towards presynaptic synthesis of CNS monoamine neurotransmitters. By facilitating the synthesis of dopamine and norepinephrine in the brain, SAMe is likely to ameliorate the symptoms of nicotine withdrawal, thus improving tobacco abstinence rates in smokers who are trying to stop smoking. SAMe is well tolerated and is available over-the-counter. To date, no prospective clinical trial evaluating the efficacy of SAMe for the treatment of tobacco dependence has been published. We propose to evaluate the efficacy of SAMe for increasing smoking abstinence and decreasing nicotine withdrawal symptoms in a randomized, blinded, placebo-controlled, three-arm, parallel-group, dose-ranging phase II clinical trial. Participants (N=120) will be randomly assigned to one of the three groups, and will receive an 8-week course of SAMe 800-mg per day, 1600-mg per day, or a matching placebo. This study is anticipated to provide the data needed to develop a larger randomized controlled clinical trial submitted through the R01 funding mechanism, if the results appear promising.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Dopamine Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000276 ↗ Dopamine Reuptake Inhibitors of Cocaine Abuse - 1 Terminated National Institute on Drug Abuse (NIDA) Phase 1 1994-09-01 The purpose of this study is to evaluate dopamine reuptake inhibitors for cocaine abuse.
NCT00000276 ↗ Dopamine Reuptake Inhibitors of Cocaine Abuse - 1 Terminated VA Connecticut Healthcare System Phase 1 1994-09-01 The purpose of this study is to evaluate dopamine reuptake inhibitors for cocaine abuse.
NCT00000276 ↗ Dopamine Reuptake Inhibitors of Cocaine Abuse - 1 Terminated Yale University Phase 1 1994-09-01 The purpose of this study is to evaluate dopamine reuptake inhibitors for cocaine abuse.
NCT00000309 ↗ Serotonin/Dopamine Antagonism of Cocaine Effect: 1 - 1 Terminated National Institute on Drug Abuse (NIDA) Phase 2 1994-08-01 The purpose of this study is to evaluate use of risperidone with cocaine abusers. Study measures incorporate an appropriate integration of behavioral and neurobiological indices.
NCT00000309 ↗ Serotonin/Dopamine Antagonism of Cocaine Effect: 1 - 1 Terminated VA Boston Healthcare System Phase 2 1994-08-01 The purpose of this study is to evaluate use of risperidone with cocaine abusers. Study measures incorporate an appropriate integration of behavioral and neurobiological indices.
NCT00000309 ↗ Serotonin/Dopamine Antagonism of Cocaine Effect: 1 - 1 Terminated Butler Hospital Phase 2 1994-08-01 The purpose of this study is to evaluate use of risperidone with cocaine abusers. Study measures incorporate an appropriate integration of behavioral and neurobiological indices.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dopamine Hydrochloride

Condition Name

Condition Name for Dopamine Hydrochloride
Intervention Trials
Schizophrenia 98
Parkinson Disease 74
Parkinson's Disease 72
Healthy 33
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Dopamine Hydrochloride
Intervention Trials
Parkinson Disease 173
Schizophrenia 106
Disease 76
Depression 66
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Dopamine Hydrochloride

Trials by Country

Trials by Country for Dopamine Hydrochloride
Location Trials
United States 934
Canada 82
Germany 64
France 55
United Kingdom 43
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Dopamine Hydrochloride
Location Trials
New York 82
California 77
Maryland 69
Massachusetts 55
Texas 50
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Dopamine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Dopamine Hydrochloride
Clinical Trial Phase Trials
Phase 4 204
Phase 3 131
Phase 2/Phase 3 36
[disabled in preview] 423
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Dopamine Hydrochloride
Clinical Trial Phase Trials
Completed 569
Recruiting 138
Unknown status 95
[disabled in preview] 163
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Dopamine Hydrochloride

Sponsor Name

Sponsor Name for Dopamine Hydrochloride
Sponsor Trials
National Institute on Drug Abuse (NIDA) 64
National Institute of Mental Health (NIMH) 45
Yale University 29
[disabled in preview] 73
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Dopamine Hydrochloride
Sponsor Trials
Other 1338
Industry 242
NIH 192
[disabled in preview] 31
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials, Market Analysis, and Projections for Dopamine Hydrochloride

Introduction

Dopamine hydrochloride is a crucial medication used in various medical conditions, including the treatment of shock, cardiovascular diseases, and certain neurological disorders. This article will delve into the current state of clinical trials, market analysis, and future projections for dopamine hydrochloride.

Clinical Trials and Medical Applications

Current Uses

Dopamine hydrochloride is widely used to treat hemodynamic imbalances, such as those resulting from shock, myocardial infarction, trauma, and renal failure. It is also employed in managing certain cardiovascular conditions, including shock and heart failure, by stimulating dopamine receptors and promoting cardiac output[5].

Ongoing and Related Trials

While there are no specific ongoing clinical trials solely focused on dopamine hydrochloride, its application in broader medical contexts is significant. For instance, dopamine agonists, which activate dopamine receptors, are being studied in various neurological and cardiovascular trials. In the context of Parkinson’s disease, dopamine agonists are used to reduce motor fluctuations, and ongoing clinical trials are assessing their efficacy and safety[3].

Market Analysis

Market Size and Growth

The dopamine hydrochloride injection market was valued at USD 1.2 billion in 2023 and is projected to reach USD 2.5 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 9.5% from 2024 to 2031. This growth is driven by the increasing prevalence of heart illnesses, the need for efficient treatments for low blood pressure and cardiac arrest, and advancements in medical technology and healthcare infrastructure[2].

Geographical Segmentation

The market is segmented geographically into North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. North America currently dominates the market due to advanced treatment options and well-developed healthcare infrastructure. However, the Asia-Pacific region is expected to show significant growth due to the steady development of healthcare infrastructure and increasing government investments in research and development[2].

Product Segmentation

The market is also segmented by product concentration, including 200mg/250ml, 400mg/250ml, and 800mg/250ml. This segmentation helps in understanding the demand for different dosages and formulations, which is crucial for manufacturers and healthcare providers[2].

Factors Influencing Market Growth

Increased Prevalence of Heart Illnesses

The rising incidence of cardiovascular diseases is a major driver for the dopamine hydrochloride market. As more people require treatments for conditions like shock and heart failure, the demand for dopamine hydrochloride injections increases[2].

Advancements in Medical Technology

Improvements in medical formulas and technology are enhancing the efficacy and safety of dopamine hydrochloride injections. This leads to higher adoption rates in hospitals, clinics, and recovery centers[2].

Expanding Healthcare Infrastructure

The expansion of healthcare infrastructure, particularly in developing regions, is increasing access to emergency cardiac care. This expansion is a significant factor in the growing demand for dopamine hydrochloride injections[2].

Challenges and Limitations

Economic Constraints

In some developing countries, low healthcare budgets can limit the adoption of dopamine hydrochloride injections. Additionally, the introduction of generic versions of branded drugs can impact market growth[3].

Regulatory and Patent Issues

Patent expirations of branded drugs and regulatory challenges can also hinder the market growth. However, special designations from regulatory authorities and ongoing clinical trials can mitigate some of these challenges[3].

Production and Cost Analysis

Raw Materials

The production of dopamine hydrochloride involves raw materials such as veratraldehyde, nitromethane, and hydrobromic acid. The availability and cost of these materials, along with factors like distribution, logistics, and safety standards, significantly influence the production cost and overall market dynamics[5].

Manufacturing Process

The manufacturing process of dopamine hydrochloride is complex and involves several steps, including synthesis and purification. Maintaining quality standards and ensuring compliance with regulatory requirements are crucial for manufacturers[5].

Key Takeaways

  • Market Growth: The dopamine hydrochloride injection market is expected to grow significantly, driven by the increasing prevalence of heart illnesses and advancements in medical technology.
  • Geographical Dominance: North America currently leads the market, but the Asia-Pacific region is expected to show significant growth.
  • Product Segmentation: Different concentrations of dopamine hydrochloride injections are in demand, reflecting varying clinical needs.
  • Challenges: Economic constraints, patent issues, and regulatory challenges can impact market growth.
  • Production: The availability of raw materials and compliance with quality standards are critical for dopamine hydrochloride production.

FAQs

What is the current market size of the dopamine hydrochloride injection market?

The dopamine hydrochloride injection market was valued at USD 1.2 billion in 2023[2].

What is the projected growth rate of the dopamine hydrochloride injection market?

The market is expected to grow at a CAGR of 9.5% from 2024 to 2031[2].

What are the primary drivers of the dopamine hydrochloride market?

The primary drivers include the increasing prevalence of heart illnesses, advancements in medical technology, and the expansion of healthcare infrastructure[2].

What are the main challenges facing the dopamine hydrochloride market?

Challenges include economic constraints in developing countries, patent expirations, and regulatory issues[3].

What are the key raw materials used in the production of dopamine hydrochloride?

The key raw materials include veratraldehyde, nitromethane, and hydrobromic acid[5].

Sources

  1. Huntington's Disease Society of America - Therapies In Pipeline
  2. Market Research Intellect - Dopamine Hydrochloride Injection Market Size And Forecast
  3. Data Bridge Market Research - Global Dopamine Agonist Drug Market
  4. MND Association - MND SMART
  5. Procurement Resource - Dopamine Hydrochloride Production Cost Analysis Reports 2024

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.